Innovent Biologics Receives Fast Track Designation for IBI363 in Melanoma Treatment
Wednesday, September 04, 2024
Innovent Biologics has received fast track designation from the U.S. Food and Drug Administration (FDA) for its PD-1 / IL-2α-bias bispecific antibody fusion protein, IBI363.
Developed by Innovent Biologics, IBI363 is a bispecific antibody fusion protein that is PD-1/IL-2α-bias and is the first of its kind. It has an uncommon capacity to block the PD-1/PD-L1 path while selectively activating IL-2 path thus improving immune response against tumors.
Melanoma, which comes from melanocytes, is the fifth most prevalent cancer in United States. Although only 3% of skin cancers are this disease, it has highest mortality rate and also more prone to metastasis compared to other types of skin cancer.
In China both incidence and death rates due to melanoma are on the increase. The classification of melanoma depends on where it occurs, with types including cutaneous, acral and mucosal melanoma. The characteristics and treatment of melanoma among Chinese patients are significantly different from those of Europeans or Americans. Advanced melanomas with BRAF V600 mutation should be given targeted therapies such as BRAF inhibitors together with MEK inhibitors.
Chemotherapy plus anti-angiogenic drugs is usually the first line therapy for people who do not have such mutation. Immunotherapy has not been approved yet in China as a first-line treatment but if these antibodies were not used at first, then they can be considered for second-line therapy instead. Limited options are available for advanced mucosal melanoma and subsequent therapies.
The designation applies to IBI363 intended for use in patients with unresectable locally advanced or metastatic melanoma (excluding choroidal melanoma) who have shown progression after at least one line systemic therapy including a PD-1 / L1 inhibitor. Clinical trials are currently underway in China, United States, and Australia as part of Phase 1/2 studies aimed at assessing the safety and effectiveness of IBI363 in various severe forms of cancer.
In its multiple-myoma study with individuals who were on immune therapy previously, Innovent came forth with quite hopeful outcomes. The individuals who took IBI363 at a daily dosage of 1 mg/kg out of 37 recorded 11 objective responses; one complete response and ten being partial responses translating into an overall response rate (ORR) of 29.7% and a disease control rate (DCR) of 73.0%.
Having shown impressive efficacy as well as safety profiles among post-immunotherapy patients; this investment firm remain determined to carry out more research into its use in managing immune resistant tumors attributable to melanoma.
By retaining its affinity for IL-2Rα and decreasing its binding to IL -2 Rβ and IL-2 Rγ the IL-2 element of IBI363 has been specifically designed so as to reduce toxicity. The PD-1 component obstructs PD-1 and localizes IL - 2 activity on tumor specific T cell population which contain both PD -1 and IL -2 Rα resulting into a precise targeting system.
In preclinical models, IBI363 manifested significant anti-tumor activity especially in overcoming PD-1 resistance mechanism and controlling metastasis. Currently there are ongoing clinical trials aimed at establishing safety profile and effectiveness of the drug among patients with advanced tumors.
Source: innoventbio.com
